Proteome Sciences PLC Investor Presentation
11 August 2022 - 4:00PM
RNS Non-Regulatory
TIDMPRM
Proteome Sciences PLC
11 August 2022
REACH: non-regulatory announcement*
11 August 2022
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Investor Presentation
Proteome Sciences plc is pleased to announce that Chief
Executive Officer, Dr Mariola Soehngen, will provide a live
presentation relating to Interim Results via the Investor Meet
Company platform on 18th August 2022 at 10:30am BST.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9am the day before the
meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet Proteome Sciences plc via:
https://www.investormeetcompany.com/proteome-sciences-plc/register-investor
Investors who already follow Proteome Sciences plc on the
Investor Meet Company platform will automatically be invited.
For further information please contact:
Proteome Sciences plc
Dr Mariola Soehngen, Chief Executive Tel: +44 (0)20 7043 2116
Officer
Dr Ian Pike Chief Scientific Officer
Richard Dennis, Chief Commercial Officer
Allenby Capital Limited (AIM Nominated Adviser & Broker)
John Depasquale / Jeremy Porter Tel: +44 (0) 20 3328 5656
About Proteome Sciences plc. ( www.proteomics.com )
Proteome Sciences plc is a specialist provider of contract
proteomics services to enable drug discovery, development and
biomarker identification, and employs proprietary workflows for the
optimum analysis of tissues, cells and body fluids. SysQuant(R) and
TMT(R)MS2 are unbiased methods for identifying and contextualising
new targets and defining mechanisms of biological activity, while
analysis using Super-Depletion and TMTcalibrator(TM) provides
access to over 8,500 circulating plasma proteins for the discovery
of disease-related biomarkers. Targeted assay development using
mass spectrometry delivers high sensitivity, interference-free
biomarker analyses in situations where standard ELISA assays are
not available.
Company has its headquarters in London, UK, with laboratory
facilities in Frankfurt, Germany.
*About Reach announcements
This is a Reach announcement. Reach is an investor communication
service aimed at assisting listed and unlisted (including AIM
quoted) companies to distribute media only / non-regulatory news
releases into the public domain. Information required to be
notified under the AIM Rules for Companies, Market Abuse Regulation
or other regulation would be disseminated as an RNS regulatory
announcement and not on Reach.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGPUCURUPPGMU
(END) Dow Jones Newswires
August 11, 2022 02:00 ET (06:00 GMT)
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Oct 2024 to Nov 2024
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Nov 2023 to Nov 2024